Lung adenocarcinoma (LUAD) is the most prevalent form of lung cancer and has been found to have multiple somatic mutations in kinase genes, among which EGFR is the most prevalent, that are treated with tyrosine kinase inhibitor (TKI) therapy1. Here, EGFR is linked to lung adenocarcinoma.